ExploreWatchlistsPricing
  1. JP-listed companies
  2. HEALIOS K.K.
  3. Financials
  4. Operating margin (%)

HEALIOS K.K. (4593)

Market cap
¥50.1B
P/E ratio
Helios develops stem cell treatments for hard-to-treat diseases using both somatic stem cells and iPS cells to create regenerative medicines.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndOperating margin (%) YoY (%)
Dec 31, 2025-3,211.5+532.59%
Dec 31, 2024-507.7-81.82%
Dec 31, 2023-2,792.6-51.47%
Dec 31, 2022-5,754.4-56.18%
Dec 31, 2021-13,131.7-15.24%
Dec 31, 2020-15,492.6+222.84%
Dec 31, 2019-4,798.9-43.46%
Dec 31, 2017-8,487.7+87.88%
Dec 31, 2016-4,517.6+318.21%
Dec 31, 2015-1,080.2+432.22%
Dec 31, 2014-203

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat